Insights into Inotropic Agents Market: Global Trends and Analysis

The inotropic agents market size has grown rapidly in recent years. It will grow from $2.32 billion in 2023 to $2.59 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to education and awareness initiatives, expansion of cardiac treatment options, development of safer agents, improved patient outcomes, regulatory approvals.

The inotropic agents market size is expected to see rapid growth in the next few years. It will grow to $4.01 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to growing cardiovascular disease burden, advancements in drug delivery systems, personalized medicine approach, increasing research funding, demand for combination therapies. Major trends in the forecast period include patient education and awareness, targeting cardiomyopathies, focus on heart failure management, combination therapies, improved safety profiles.

Market Overview -
Inotropic agents refer to a class of medications that affect the contractility of the heart muscle. They are used to treat conditions such as heart failure, where the heart is unable to pump enough blood to meet the body's needs. Inotropic agents work by increasing the strength and force of the heart's contractions, which can improve blood flow to the body's organs and tissues.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=10711&type=smp

Surging Cardiovascular Diseases Propel Growth In The Inotropic Agent Market
The surge in the prevalence of cardiovascular diseases is driving the inotropic agent market. Cardiovascular diseases (CVDs) refer to diseases of the vascular system and heart functioning. Inotropic agents are used in the treatment of cardiovascular diseases to improve the contractility and function of the heart, tackle cardiac shock, and slow the heart rate as they help the heart contract more powerfully, thereby increasing blood flow. So this helps boost the inotropic agent market. For instance, in October 2022, according to the reports shared by the Centers for Disease Control and Prevention, a US-based government agency, heart diseases were the leading cause of death in the US. About 697,000 people died from heart disease in 2020, which was roughly 1 in every 5 deaths. About 20.1 million adults were suffering from coronary artery disease. Each year, about 805,000 people in the US suffer from a heart attack. Furthermore, in August 2022, according to the American College of Cardiology, a US-based nonprofit medical association, the risk of stroke was expected to increase by 33.8 percent to 15 million from 2025 to 2060. Therefore, the surge in the prevalence of cardiovascular diseases is propelling the inotropic agent market forward.

Competitive Landscape -
Major companies operating in the inotropic agents market report are Pfizer Inc., GSK plc, Novartis AG, Mylan N.V., Boehringer Ingelheim International GmbH, AstraZeneca plc, Johnson & Johnson, Bayer AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Cipla Ltd., Eli Lilly And Company, Sanofi S.A., Baxter International Inc., Hikma Pharmaceuticals plc, Sun Pharmaceuticals Industries Ltd., Cadila Pharmaceuticals Ltd., AbbVie Inc., Allergan plc, Amgen Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Fresenius Kabi AG, Genentech Inc., GlaxoSmithKline plc, Intas Pharmaceuticals Ltd., Lupin Limited, Regeneron Pharmaceuticals Inc., Roche Holding AG, BioNTech SE

Bristol-Myers Squibb's Mavacamten Receives Fda Approval, Setting A Trend In The Inotropic Agents Market
Drug approval is a key trend gaining popularity in the inotropic agents market. Major companies in the market are developing innovative new products and drugs to sustain their position in the market. For instance, in April 2022, Bristol-Myers Squibb., a US-based pharmaceutical developer and manufacturer, received regulatory approval for Camzyos™ (mavacamten) from the U.S. Food and Drug Administration (FDA), a US-based national public health agency and regulator. It is used in the treatment of class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. This medication works by inhibiting the excessive contraction of the heart muscle. It is a selective inhibitor of cardiac myosin, a protein involved in muscle contraction. It is typically prescribed to individuals who have symptomatic obstructive HCM and have not adequately responded to other treatment options, such as beta-blockers or calcium channel blockers.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/inotropic-agents-global-market-report

Key Segments -

The inotropic agents market covered in this report is segmented -

1) By Type: Positive Inotropic Drugs, Negative Inotropic Drugs, Other Types
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By Indication: Heart Attack, Heart Failure, Angina, Arrhythmia, Other Indications
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
5) By End User: Hospital, Homecare, Specialty Centers, Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.